Trials / Completed
CompletedNCT00516438
Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Topotecan
A Phase I, Open-Label, Study of the Safety and Tolerability of KU-0059436 and Topotecan in the Treatment of Patients With Advanced Solid Tumours
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 48 (estimated)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to identify a safe and tolerable dose of the drug KU-0059436 that can be given in combination with topotecan chemotherapy in patients with advanced solid tumours
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | KU-0059436 (AZD2281)(PARP inhibitor) | oral |
| DRUG | Topotecan | intravenous infusion |
Timeline
- Start date
- 2007-07-01
- Primary completion
- 2009-03-01
- Completion
- 2009-11-01
- First posted
- 2007-08-15
- Last updated
- 2010-12-08
Locations
3 sites across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT00516438. Inclusion in this directory is not an endorsement.